Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke

INTRODUCTION: Stroke is a common cause of epilepsy that may be mediated via glutamate dysregulation. There is currently no evidence to support the use of antiseizure medications as primary prevention against poststroke epilepsy. Perampanel has a unique antiglutamatergic mechanism of action and may h...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolo, John-Paul, Chen, Zhibin, Moffat, Bradford, Wright, David K, Sinclair, Benjamin, Glarin, Rebecca, Neal, Andrew, Thijs, Vincent, Seneviratne, Udaya, Yan, Bernard, Cloud, Geoffrey, O'Brien, Terence J, Kwan, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112439/
https://www.ncbi.nlm.nih.gov/pubmed/33972334
http://dx.doi.org/10.1136/bmjopen-2020-043488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112439/
https://www.ncbi.nlm.nih.gov/pubmed/33972334
http://dx.doi.org/10.1136/bmjopen-2020-043488

Ejemplares similares